27th WONCA Europe Conference 2022 woncaeurope2022.org
Company:Novo Nordisk Ltd.
Title: WHAT ROLE DOES AN ORAL GLP-1 RECEPTOR AGONIST HAVE IN ADULTS WITH TYPE 2 DIABETES IN PRIMARY CARE. A CASE BASED DISCUSSION.*
Date: Thursday 30.6.
Time: 12:30 - 13:30
Location: Room 4
*This is a promotional symposium for Healthcare professionals only, organised and funded by Novo Nordisk.
This face to face session will help attendees understand the progressive nature of Type 2 Diabetes and the importance of glycaemic control, and also to understand the considerations for when is the right time to start an oral GLP-1 (glucagon-like peptide-1), receptor agonist treatment. The session will go onto explore relevant RYBELSUS ®▼ (semaglutide tablets) clinical data and the potential implications on adult Type 2 Diabetes care.
Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in combination with other medicinal products for the treatment of diabetes.
Novo Nordisk products will be discussed. UK Prescribing information for Rybelsus will be available at this meeting and can also be found here: https://www.emcpi.com/pi/38345. Registration conditions may differ internationally, always consult your local Prescribing Information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Stores.
Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 0232573). Calls may be monitored for training purposes.
Job bag: UK22DI00248 Date of Prep: Jun-2022
© Copyright CONFEA